ECG changes in pediatric patients on tricyclic antidepressants, desipramine, and imipramine

Canadian Journal of Psychiatry

Volumn 41, Issue 2, 1996, Pages 102-106

  Johnson, Amanda ^a,b   Giuffre, R Michael ^c,d   O'Malley, Keiran ^e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d ALBERTA CHILDREN'S HOSPITAL   (Canada)

^e Cardiology Clinic ^*

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; IMIPRAMINE; PERICIAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; DEPRESSION; ELECTROCARDIOGRAM; HEART FUNCTION; HUMAN; QT INTERVAL; SCHOOL CHILD; SUDDEN DEATH;

EID: 0029922059     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379604100207     Document Type: Article

References (30)

1. Tingelstad JB. Clinical comment: the cardiotoxicity of tricyclics. J Am Acad Child Adolesc Psychiatry 1991;30:845-846.
2. Marshall JB, Forker AD. Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications. Am Heart J 1982;103:401-413.
3. Donnelly M, Zametkin AJ, Rapoport JE. Treatment of childhood hyperreactivity with desipramine plasma drug concentrations, cardiovascular effects, plasma and urinary catecholamine levels and clinical response. Clin Pharmacol Ther 1986;39:72-81.
4. Biederman J, Gastfriend DR, Jellinek MS. Cardiovascular effects of desipramine in children and adolescents with ADD. J Pediatrics 1985;100:1017-1020.
5. Schroeder JS, Mullin AV, Elliott GR, and others. Cardiovascular effects of desipramine in children. J Am Acad Child Adolesc Psychiatry 1989;28:376-379.
6. Wilens AJ, Biederman J, Baldessarini RJ, and others. Developmental changes in serum concentrations of desipramine (DMI) and 2-hydroxydesipramine (OHDMI) during treatment with desipramine. Psychiatry 1992;31:691-698.
7. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 1977;18:137-165.
8. Biederman J, Jellinek MS. Psychopharmacology in children. N Engl J Med 1984;310:968-972.
9. Goyer PF, Davis GC, Rapoport JL. Abuse of prescribed stimulant medication by a 13 year old hyperactive boy. J Am Acad Child Adolesc Psychiatry 1982;18:1170-1175.
10. Zametkin A, Rapoport JL. Tricyclic antidepressants in children. In: Burrows GD, Norma TR, Davies B, editors. Drugs in psychiatry. Vol 1. Antidepressants. Amsterdam: Elsevier; 1983. p 129-147.
11. Greenberg L, Yellin A, Spring C, and others. Clinical effects of imipramine and methylphenidate in hyperactive children. Int J Ment Health 1975; 4:144-156.
12. Rapoport JL, Quinn P, Bradbard G, and others. Imipramine and methylphenidate treatment in hyperactive boys: a double-blind comparison. Arch Gen Psychiatry 1974;30:789-793.
13. Werry J. Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry 1980;21:27-35.
14. Garfinkel BD, Wender PH, Sloman L. Tricyclic antidepressants and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Adolesc Psychiatry 1983;2:343-348.
15. Biederman J, Baldessarini RJ, Wright V, and others. A double-blind controlled study of desipramine in the treatment of ADD: II serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry 1989;28:903-911.
16. Biederman J. Sudden death in children treated with a tricyclic antidepressant. J Am Acad Child Adolesc Psychiatry 1991; 495-498.
17. Glassman AH, Bigger JT. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. Arch Gen Psychiatry 1981;38:815-820.
18. Biggs JT. Clinical pharmacology and toxicology of antidepressants. Hosp Pract 1978;11:79.
19. Nelson JC, Mazure C, Jatlow PI. Clinical implications of the pharmokinetics of tricyclic antidepressants. In: Dahl SG, Gram LF, editors. Clinical pharmacology in psychiatry. New York: Springer Verlag; 1989. p 205-219.
20. Coull DC, Crooks J, Dingwall-Fordyce I, Scott AM, Wier RD. Amitriptyline and cardiac disease: risk of sudden death identified by monitoring system. Lancet 1970;2:590-591.
21. Moir DC, Dingwall-Fordyce I, Weir RD. Medicines evaluation and monitoring group: a follow-up study of cardiac patients receiving amitriptyline. Eur J Clin Pharmacol 1973;6:98-101.
22. Jefferson JW. A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom Med 1975;35:160-179.
23. Bartels MG, Varely CK, Mitchell J, and others. Pediatric cardiovascular effects of imipramine and desipramine. J Am Acad Child Adolesc Psychiatry 1990;30:100-103.
24. Kantor SJ, Glassman AH, Bigger JT, Percel JM, Giardina EV. The cardiac effects of therapeutic plasma concentrations of imipramine. Am J Psychiatry 1978;135:534-538.
25. Riddle MA, Nelson JC, Kleinman CS, and others. Sudden death in children receiving norpramine: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 1990;30:104-108.
26. Zareba W, Moss AJ, Cessie S, and others. T wave alternans in idiopathic Long QT Syndrome. J Am Coll Cardiol 1994:1541-1546.
27. Pringle TH, Scobie IN, Murray RG, and others. Prolongation of the QT interval during therapeutic starvation: a substrate for malignant arrhythmias. Int J Obst 1983;7:253-261.
28. Burckhart D, Raeder E, Muller V, Imhof P, Neubauer H. Cardiovascular effects of tricyclic and tetracyclic antidepressants. J Am Med Assoc 1978;239:213-216.
29. Safar KR, Klein DF, Gittelman R, and others. EKG effects of imipramine and treatment in children. J Am Acad Child Adolesc Psychiatry 1978;17:60-69.
30. Weiss A, Hechtman Trokenberg L. Hyperactive children grow up. New York: The Guilford Press; 1993.